Skip to main content
Eyal Attar, MD, Oncology, Boston, MA

Eyal C Attar MD

Oncology•Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Massachusetts General Hospital

Join to view full profile

  • 55 Fruit StYaw 7B Hematology OncologyBoston, MA 02114

  • Phone+1 617-726-8731

  • Fax+1 617-726-4691

Dr. Attar is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Attar's full profileAlready have an account?

Education & Training

  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2000 - 2027

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017

Publications & Presentations

PubMed

Journal Articles

  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

  • Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
    Eyal C. Attar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
    Eyal C. Attar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
    PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted TherapiesSeptember 6th, 2024
  • Vor Bio Appoints Eyal C. Attar, M.D. As Chief Medical Officer
    Vor Bio Appoints Eyal C. Attar, M.D. As Chief Medical OfficerOctober 12th, 2022
  • Aprea's Myeloid Program Iced by FDA While Tricky Adverse Event Profile Is Sorted Out
    Aprea's Myeloid Program Iced by FDA While Tricky Adverse Event Profile Is Sorted OutAugust 6th, 2021

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Eyal Attar, Dr. Eyal Attar, MD, Dr. E Attar, Dr. Eyal C Attar